Correction: Sustained blood pressure reduction associated with percutaneous auricular vagus nerve stimulation in hypertensive chronic pain patients: a retrospective dual-center analysis - Scorecard - MDSpire

Correction: Sustained blood pressure reduction associated with percutaneous auricular vagus nerve stimulation in hypertensive chronic pain patients: a retrospective dual-center analysis

  • By

  • Laurenz Berger

  • Rudolf Likar

  • Christophe Perruchoud

  • Stefan Kampusch

  • Van Hoang Le

  • Klaus Zeiner

  • Caroline Stremnitzer

  • Francesco Moscato

  • Max Haberbusch

  • May 6, 2026

  • 0 min

Share

Clinical Scorecard: Correction: Long-term reduction in blood pressure linked to percutaneous auricular vagus nerve stimulation in patients with chronic pain and hypertension: a retrospective analysis from two centers

At a Glance

CategoryDetail
ConditionChronic pain and hypertension
Key MechanismsPercutaneous auricular vagus nerve stimulation
Target PopulationPatients with chronic pain and hypertension
Care SettingDual-center clinical study

Key Highlights

  • Sustained blood pressure reduction observed
  • Retrospective analysis from two centers
  • Focus on chronic pain patients
  • Vagus nerve stimulation as a potential treatment
  • Acknowledgements for contributions to the study

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Hypertensive chronic pain patients

          Long-term effects of vagus nerve stimulation on blood pressure

          Clinical Best Practices

            References

            Original Source(s)

            Correction: Sustained blood pressure reduction associated with percutaneous auricular vagus nerve stimulation in hypertensive chronic pain patients: a retrospective dual-center analysis

            • by Laurenz Berger, Rudolf Likar, Christophe Perruchoud, Stefan Kampusch, Van Hoang Le, Klaus Zeiner, Caroline Stremnitzer, Francesco Moscato, Max Haberbusch

            • May 6, 2026

            Related Content

            Ensitrelvir Reduced COVID After Household Exposure

            In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

            AD Not Linked to Early CV Risk Markers

            Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

            Evaluation of a pharmacist-led digital hypertension management program in a tertiary hospital in Singapore